EP. 3 Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens
EP. 6 Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways
November 9th, 2026Melflufen Gains EU Expansion in Third-Line Lenalidomide-Refractory Multiple MyelomaThe decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.Read more
November 9th, 2026FDA Flashback: Hematologic Cancer Decisions and News From October 2026Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.Read more
November 9th, 2026BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R MyelomaDuring a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.Read more